Stable Disease Control and Reduced Flare Rates with Lebrikizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s835
DOI: 10.25251/jtfsst34 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Vikash Oza und 8 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic, fluctuating, unpredictable inflammatory skin disease characterized by recurrent flares. Over 20% of adolescents with moderate-to-severe AD have ≥12 flares per year. Flare frequency correlates with disease severity and quality-of-life impairment, underscoring the importance of flare as a clinically meaningful outcome. Lebrikizumab is a high-affinity monoclonal antibody that selectively binds interleukin-13, a key cytokine in AD. Week 16 lebrikizumab responders from the ADvocate 1 and 2 (NCT04146363, NCT04178967) trials who continued treatment in the ADjoin (NCT04392154) long-term extension study showed that most participants maintained a stable EASI 75 response through 3 years with no or minimal flares. However, the stability of response and flare-free status among adolescent responders has not been characterized.
Objective
To evaluate the long-term stability of response and flare-free disease control through Week 152 among adolescent Week 16 lebrikizumab responders with moderate-to-severe AD from ADvocate1 and ADvocate 2 who continued treatment in ADjoin.
Methods
This post-hoc analysis included adolescent (≥12 to
Zitieren
APA
Oza, V., Gonzalez, M., Burnette, A., Chovatiya, R., Montmayeur, S., Yang, C., Li, Y., Sinibaldi, T. L., & Carrascosa, J. M. (2026). Stable Disease Control and Reduced Flare Rates with Lebrikizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 10(6), s835. https://doi.org/10.25251/jtfsst34
Vancouver
Oza V, Gonzalez M, Burnette A, Chovatiya R, Montmayeur S, Yang C, et al. Stable Disease Control and Reduced Flare Rates with Lebrikizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s835. doi:10.25251/jtfsst34
BibTeX
@article{Oza2026,
author = {Oza, Vikash and Gonzalez, Mercedes and Burnette, Autumn and Chovatiya, Raj and Montmayeur, Sonia and Yang, Chao and Li, Yi and Sinibaldi, Tommaso Lupieri and Carrascosa, Jose Manuel},
title = {Stable Disease Control and Reduced Flare Rates with Lebrikizumab in Adolescents with Moderate-to-Severe Atopic Dermatitis},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s835},
doi = {10.25251/jtfsst34}
}
EUVIMED